Allurion Technologies, INC 8-K filings

Allurion Technologies announced a debt restructuring through an exchange of common stock for pre-funded warrants and the termination of a prior purchase agreement.

Allurion Technologies announces the immediate resignation of CEO Shantanu K. Gaur, with COO Ojas Buch to manage daily operations.

Allurion Technologies, Inc. announced the resignation of director Douglas Hudson from its Board and Nominating and Corporate Governance Committee, effective June 30, 2026.

Allurion Technologies, Inc. announced the resignation of R. Jason Richey from its Board of Directors and as Chairperson of the Audit Committee, effective June 24, 2026.

Allurion Technologies, Inc. has implemented a 1-for-15 reverse stock split to regain compliance with NYSE listing standards and advance its relisting strategy.

Allurion Technologies, Inc. announced the dismissal of Deloitte & Touche LLP as its independent registered public accounting firm and the appointment of CBIZ CPAs P.C., citing material weaknesses in internal controls.

Allurion Technologies, Inc. has been notified of delisting from the NYSE due to market capitalization non-compliance, but the company is appealing the decision and executing a plan to relist.

Allurion Technologies received a NYSE delisting notice due to non-compliance with listing standards but plans to appeal, expecting continued trading during the process.

Allurion Technologies secures $3.0 million in gross proceeds by inducing warrant holders to exercise existing warrants at a reduced price and issuing new warrants.

Allurion Technologies, Inc. announced U.S. FDA approval for its Allurion Gastric Balloon System, featuring the Allurion Smart Capsule, for obesity treatment.

Allurion Technologies announced preliminary unaudited fourth quarter and full-year 2025 results, showing significant quarter-over-quarter revenue growth and improved operating metrics.

Allurion Technologies, Inc. stockholders re-elected directors, ratified auditors, and approved several key proposals including an amended equity plan, option repricing, and a potential reverse stock split at their 2025 Annual Meeting.

Allurion Technologies strengthens its balance sheet with a $5 million private placement and a debt-to-equity exchange, while achieving significant FDA milestones for its Smart Capsule.

Milena Alberti-Perez has resigned from Allurion Technologies' board and as Audit Committee chair, reducing board size for efficiency and cost savings.

Allurion Technologies, Inc. announced that its Audit Committee concluded certain previously issued financial statements should no longer be relied upon due to accounting errors related to fair value of financing instruments.

Allurion Technologies reports a significant revenue decline in Q2 2025, alongside a strategic shift towards GLP-1 combination therapy and a potential financial restatement.

Allurion Technologies announces a strategic shift towards low-dose GLP-1 combination therapy and US market entry, alongside a significant workforce reduction and preliminary Q2 2025 financial results.

Allurion Technologies announces its Q1 2025 financial results, highlighting a decrease in operating expenses and maintaining its 2025 revenue guidance of approximately $30 million.

Allurion Technologies amends its Note Purchase Agreement with RTW Investments, triggering potential mandatory conversion of notes into common stock due to a market capitalization dip below $15 million.

Allurion Technologies' stockholders approved several proposals at a special meeting, including the repricing of warrants and amendments to a note purchase agreement to adjust conversion prices based on market capitalization.

Allurion Technologies has postponed its special stockholder meeting to April 10, 2025, to allow for more time to solicit proxies and encourage broader stockholder participation.

Allurion Technologies announces its Q4 and full-year 2024 financial results, highlighting revenue, expense reductions, and progress in clinical trials and market access.

Allurion Technologies has successfully raised approximately $6.1 million through an offering and concurrent private placement to support its clinical pipeline focused on GLP-1 therapies.

Allurion Technologies announces the relaunch of its Allurion Balloon in France following clearance from the French regulatory authority, ANSM, and is considering clinical trials combining the balloon with GLP-1s.

Allurion Technologies, Inc. has secured $7.4 million in gross proceeds through a registered direct offering and concurrent private placement to support working capital and general corporate needs.

Allurion Technologies announces a $2.5 million private placement with RTW Investments, LP, to extend its financial runway and support its 2025 strategic plan.

Allurion's AUDACITY trial demonstrates significant weight loss and a favorable safety profile for the Allurion Balloon at 48 weeks.

Allurion Technologies has appointed R. Jason Richey to its Board of Directors, effective December 30, 2024, filling a newly created vacancy.

Allurion Technologies will implement a 1-for-25 reverse stock split effective January 3, 2025, to increase its stock price and regain compliance with NYSE listing standards.

Allurion Technologies' stockholders approved several key proposals at their reconvened 2024 annual meeting, including a reverse stock split and the issuance of shares related to debt and preferred stock conversions.